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Despite a strong correlation to outcome, the measurement of gray matter (GM) atrophy
is not being used in daily clinical practice as a prognostic factor and monitor the effect of
treatments in Multiple Sclerosis (MS). This is mainly because the volumetric methods
available to date are sophisticated and difﬁcult to implement for routine use in most
hospitals. In addition, the meanings of raw results from volumetric studies on regions
of interest are not always easy to understand.Thus, there is a huge need of a methodology
suitable to be applied in daily clinical practice in order to estimate GM atrophy in a
convenient and comprehensive way. Given the thalamus is the brain structure found to
be more consistently implied in MS both in terms of extent of atrophy and in terms of
prognostic value, we propose a solution based in this structure. In particular, we propose
to compare the extent of thalamus atrophy with the extent of unspeciﬁc, global brain
atrophy, represented by ventricular enlargement. We name this ratio the “yearly rate of
RelativeThalamic Atrophy” (yrRTA). In this report we aim to describe the concept of yrRTA
and the guidelines for computing it under 2D and 3D approaches and explain the rationale
behind this method.We have also conducted a very short crossectional retrospective study
to proof the concept of yrRTA. However, we do not seek to describe here the validity of
this parameter since these researches are being conducted currently and results will be
addressed in future publications.
Keywords: biomarker, gray matter, Multiple Sclerosis, atrophy, thalamus, clinically isolated syndrome, planimetry
INTRODUCTION
Several studies have demonstrated that, on average, brain volume
decreases by about 0.6–1% yearly in patients with Multiple Sclero-
sis (MS). Brain atrophy may involve both white matter (WM) and
gray matter (GM; Miller et al., 2002). Although lower WM vol-
ume is associated with greater disability in MS, a study found WM
volume on average in the normal range (Shiee et al., 2012). This
paradoxical result might be explained by the presence of coex-
isting pathological processes, such as tissue damage and repair,
that cause both atrophy and hypertrophy and that underlie the
observed disability. GM damage is common and widespread in
MS, especially in chronic MS but also in early stages, develop-
ing gradually following the appearance of inﬂammatory lesions
(Miller et al., 2002). The underlying pathological correlates of
GM damage in MS are different from WM damage. This prob-
ably reﬂects both inﬂammation-induced axonal loss followed by
Wallerian degeneration and post-inﬂammatory neurodegenera-
tion that may be partly due to failure of remyelination (Mühlau
et al., 2013). However, one component of atrophy appears to be
independent of focal lesions (Hulst and Geurts, 2011; Hoshi et al.,
2013).
In contrast to GM atrophy, ventricular enlargement (VE) lacks
speciﬁcity, representing a measure of global brain atrophy. It is
well known that enlargement of lateral ventricles is a measure of
unspeciﬁc global brain atrophy since it is strongly associated both
with aging in healthy and with neurodegeneration. Almost any
neurodegenerative disorder leads to some degree of VE, and so do
some psychiatric conditions also. In MS,VE has been shown to be
due to WM atrophy, deep brain atrophy and altered cerebrospinal
ﬂuid ﬂow (Magnano et al., 2012). The exception here is the third
ventricle where enlargement do seem to represent progression of
the disease. Several studies, usingwellmagnetic resonance imaging
(MRI) well transcranial Doppler, showed that enlargement of the
third ventricle correlates with motor deﬁcits (Müller et al., 2013),
disability (Kallmann et al., 2004), and cognition (Wollenweber
et al., 2011; Müller et al., 2013) in MS.
Some authors found the pattern of atrophy is somewhat dif-
ferent in the different forms of MS: while subcortical damage
is predominant in relapsing-remitting multiple sclerosis (RRMS;
Pagani et al., 2005; Bergsland et al., 2012), cortical atrophy seems
to bemore important in the progressive forms (Pagani et al., 2005).
However, other studies found lack of association with disease
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duration and disease category, suggesting that atrophy patterns
may reﬂect different underlying mechanisms not distinguishable
by conventional disease measures (Fisher et al., 2013).
In clinically isolated syndrome (CIS) changes in subcorticalGM
were reported (Henry et al., 2008). Indeed several studies found
GM atrophy is associated with conversion to deﬁnite MS (Kalin-
cik et al., 2012; Pérez-Miralles et al., 2013; Zivadinov et al., 2013),
concluding that GM atrophy is a very good parameter to predict
progression in CIS —and perhaps other forms of MS also—.
It is very clear that GM atrophy measurements correlate
strongly with disability and cognitive impairment (more so than
WM atrophy; Pagani et al., 2005; Riccitelli et al., 2011; Roosendaal
et al., 2011; Shiee et al., 2012). The association of the distinct pat-
terns of regional distribution of GM damage with cognition seems
to depend on the clinical phenotypes: while in RRMS and SPMS
patients there is a correspondence between presences of GM atro-
phy in several areas, this is not the case in PPMS patients (Riccitelli
et al., 2011). Some brain structures also correlate better than oth-
ers: for instance, high physical disability is associated with low
thalamus and brainstem volumes but not with low cortical GM
volume (Shiee et al., 2012).
Among all GM structures, the thalamus is the most consis-
tently implied in MS. The paired thalamic nuclei on both sides of
the third ventricle play major roles in cortical activation, relaying
sensory and motor information to the higher cortical centers that
inﬂuence cognition (Herrero et al., 2002). Thalamic involvement
occurs within the ﬁrst 5 years of MS onset, when most patients are
still minimally disabled (Davies et al., 2005; Henry et al., 2008).
Thalamus volumes are inversely correlated with lesion load in MS
(Shiee et al., 2012) and thalamus atrophy (TA) is associated with a
wide range of clinical manifestations including cognitive decline,
motor deﬁcits, disability, fatigue, painful syndromes, and ocu-
lar motility disturbances in patients with MS (Hulst and Geurts,
2011; Batista et al., 2012; Shiee et al., 2012; Minagar et al., 2013).
TA is also associated with conversion from CIS to deﬁnite MS
over 2 years (Vaneckova et al., 2013; Zivadinov et al., 2013). In
addition, as TA leads to enlargement of the third ventricle, the
selective speciﬁcity of the enlargement of the third ventricle in
contrast to the unspeciﬁc enlargement of the lateral ventricles is
an indirect evidence of the involvement of the thalamus in MS
also.
THE NEED
Magnetic resonance imaging plays an ever-expanding role in
the evaluation of MS. Conventional MRI techniques, including
lesion detection from T1- or T2-weighted images, have been the
mainstay for monitoring disease activity, in which the use of
gadolinium with T1-weighted images adds additional sensitivity
and speciﬁcity for areas of acute inﬂammation. Advanced imag-
ing methods including magnetization transfer, ﬂuid attenuated
inversion recovery, diffusion, magnetic resonance spectroscopy,
functional MRI, volumetry, and nuclear imaging techniques have
added to our understanding of the pathogenesis of MS and may
provide methods to monitor therapies more sensitively in the
future. However, these advanced methods are limited by their
cost, availability, complexity, and lack of validation (Bakshi et al.,
2005).
Despite a strong correlation to outcome, the measurements
of GM atrophy is not being used in daily clinical practice as a
prognostic factor and monitor the effect of treatments in MS yet.
This is mainly because the volumetric methods available to date
are sophisticated and difﬁcult to implement for routine use in
most hospitals. In addition, the meanings of raw results from
volumetric studies on regions of interest are not always easy to
understand.
Albeit ongoing clinical trials with anti-inﬂammatory, remyeli-
nating, or neuroprotective therapies are implementing volumetric
studies for measuring atrophy as a sensitive measure of the
neurodegenerative component in MS, again these results will
be difﬁcult to translate to clinical practice. There is a lack of
connection between practice in trials and practice under real
clinical conditions and this has to be solved with a method
able to link volumetry with clinically available neuroimaging
techniques.
THE PROPOSED SOLUTION
Given the thalamus is the brain structure found to be more con-
sistently implied in MS both in terms of extent of atrophy and
in terms of prognostic value, we propose a solution based in this
structure. In particular, we propose to compare the extent of TA
with the extent of unspeciﬁc, global brain atrophy, represented by
VE. Thus, the yearly rate of Relative Thalamic Atrophy (yrRTA)
compares the extent of TA with the extent of VE measured in two
MRIs performed at two different time-points. Both the TA and
the VE can be measured using 2D (areas of regions of interest
on one MRI slice only) or 3D (volumes of regions of interest)
methodology.
In this report we aim to describe the guidelines for computing
the yrRTA. However, we do not seek to describe here the validity of
this parameter since these researches are being conducted currently
and results will be addressed in future publications.
GUIDELINES
Measures in the 2D method
In the 2D method we select the T1 sequence and take the axial slide
passing through the foramen of Monro/interthalamic adhesion.
Using the tool for measuring areas available in most DICOM
Viewer softwares, we just trace the next three regions of interest
(Figure 1):
(1) The limits of each thalamus (Duvernoy, 1991; A, A′)
• Anterior: using the anterior commissure as a starting point,
the thalamus can be identiﬁed just posterior to the com-
missure’s clearest coronal view. The anterior portion of the
thalamus is narrow, resulting in an oblong shape in the
coronal plane. It is this anterior section of the thalamus
that forms the posterior boundary of the interventricular
foramen.
• Lateral: throughout its course in the brain, the thalamus
maintains its relationship with the internal capsule until
the most posterior portion. The medial border of both the
genu and the posterior limb of the internal capsule serve as
the lateral border to the thalamus itself, thus separating the
thalamus from the adjacent lentiform nucleus.
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FIGURE 1 | Magnetic resonance imaging showing the areas needed to
compute the 2D-yrRTA:A andA’: right and left thalamus; B: ventricular
system including the lateral ventricles and the third ventricle.
• Medial: the CSF of the third ventricle serves as the medial
border of the thalamus. Where applicable, portions of the
fornix may also serve as a medial border. It is important to
note that left and right portions of the thalamus have to be
traced individually, excluding the massa intermedia when
present.
• Posterior: projecting beyond both the superior and inferior
colliculi, the thalamus protrudes posteriorly until coming
into contact with either the atrium of the lateral ventricle,
the tail of the hippocampus, or both structures.
(2) The limits of the whole ventricular system, including the lat-
eral ventricles, the third ventricle, and the posterior/occipital
horn of the lateral ventricles (B). Tracing the limits of the ven-
tricular system in 2D is very easy and do not require advanced
anatomical knowledge (Figure 1).
Measures in the 3D method
There are different approaches and methodologies for performing
volumetric studies, including manual, semi-automated, and fully
automated methods (Miller et al., 2002). Any volumetric method
is suitable for calculating the 3D-yrRTA. Usually, the tracer needs
to know the limits and boundaries of the regions of interest. Here
we need to ﬁnd out the volume of each thalamus (A, A′), each
lateral ventricles (C, C′), and the third ventricle (D).
The limits of the thalamus are as just described for the 2D
method, and in addition we need to know the upper and lower
borders of the thalamus (Duvernoy, 1991):
• Superiorly, the lateral ventricles bound the thalamus. As
one moves from anterior to posterior, the thalamus loses its
magnitude in the Y plane. This causes the coronal height of
the thalamus to decrease, thus allowing the fornix to serve
as the superior boundary in more posterior slices.
• Inferiorly, the zona incerta and its junction with the internal
capsule serve as the inferior border of the thalamus, thus
excluding the subthalamic nucleus, the substantia nigra, and
the nucleus rubor.
The anatomical limits of the lateral ventricles and third ven-
tricles are extensive, complex and difﬁcult to resume here; we
recommend consulting brain atlases for a review (i.e., Duvernoy,
1991). However, tracing the limits of these structures on MRI is
quite simple given the distinct density of CSF in contrast to the
density of any other brain structure.
Computing ratios
Thereafter, we can compute the following ratios using the formule
described in Table 1.
CLINICAL INTERPRETATION OF RESULTS
Upcoming studies will allow us to set the normal rate of TA
and the normal rate of VE. Then we will be able to classify the
results of the yrTA and the yrVE as “low” or “high” in qualitative
terms. Hereafter, the interpretation of results is easy to understand
following the comments in Table 2. The expected risk of pro-
gression can be anticipated “a priori,” according to what we know
regarding GM atrophy as marker of disability and progression
in MS.
Although the yrRTA of patients who have global brain atro-
phy including TA might be similar to that of healthy subjects this
situation is not a real challenge in clinical practice.
On one hand, patients with low yrRTA have “intact” deep GM,
so they are expected to have good prognosis and low disability and
cognitive impairment; therefore when clinicians face patients with
low yrRTA a “conservative therapy” may be allowed. On the other
hand, patients with high yrRTA are at high risk and an “aggressive
therapy” may be needed. Patients with normal yrRTA but high
yrTA and yrVE are probably those who are entering in a pro-
gressive form where neurodegeneration is becoming widespread
and an “aggressive therapy” may also be needed. This scenario
is different from that of someone who is in the latest stages of
the disease, where the yrTA is no longer high and therefore the
yrRTA is expected to be low or normal depending on the yrVE;
but again, differentiating this situation from normal aging or
low risk MS is not a real challenge since the clinical proﬁle of
these individuals is very different and easy to distinguish at ﬁrst
glance.
PROOF-OF-CONCEPT
We conducted a very short crossectional retrospective study to
proof the concept of yrRTA. It is not intended to prove the validity
of the method, but to check the feasibility only. Thus, we do not
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Table 1 | Formule for computing the yrTA, yrVE, and yrRTA under 2D and 3D methodologies.
yrTA yrVE yrRTA
2D (A1+A’1)−(A2+A’2) x 120/(#months
between MRI studies)
(B2−B1) × 120/(#months between MRI studies) (A1+A’1)−(A2+A’2) × 120/(B2−B1) × (#months
between MRI studies)
3D (A1+A’1)−(A2+A’2) × 120/(#months
between MRI studies)
(C2+C’2+D2)−(C1+C’1+D1) × 120/(#months
between MRI studies)
(A1+A’1)−(A2+A’2) × 120/(C2+C’2+D2)−
(C1+C’1+D1) × (#months between MRI
studies)
Numbers 1 and 2 represent the ﬁrst (1) and second (2) MRI studies.
Table 2 | Possible results of the yrTA, yrVE, and derived yrRTA in qualitative terms with the clinical interpretation.
yrTA yrVE yrRTA Clinical interpretation
Low Low Normal This is what we expect in a healthy subject or a patient without signiﬁcant brain atrophy (no brain atrophy ongoing) – Low risk
of progression
Low High Low This is what we expect in someone whose brain is getting atrophied but the thalamus is not (atrophy ongoing but not due to
deep GM atrophy) – Low risk of progression
High Low High This is what we expect in someone whose thalamus is getting atrophied but other brain structures are not so signiﬁcantly
(atrophy ongoing due to deep GM atrophy mostly) – High risk of progression
High High Normal This is what we expect in someone who has global brain atrophy including the thalamus (generalized atrophy ongoing) – High
risk of progression
provide here a full description of the methods nor performed
advanced statistical analysis.
Experiments conform to the relevant regulatory standards in
Europe and were approved by the Ethics Committee of Hospi-
tal Universitario Central de Asturias. Retrospectively, we took the
baseline and 1 year (9–15 months) MRIs of ﬁve patients diag-
nosed with CIS who had converted to deﬁnite MS over 24 months
and ﬁve patients diagnosed with CIS who had not converted to
MS over 24 months. We also took the baseline and 1 year (9–
15 months) MRIs of 5 age and gender matched controls. Then
we traced the areas and volumes needed for the 2D- and 3D-
yrRTA respectively using the software Osirix and computed the
ratios as explained before. The mean 2D-yrRTA was 16.4 in
controls, 16.1 in CIS who not progressed and 22.4 in CIS who
progressed to MS. The 3D-yrRTA was 17.1 in controls, 15.4 in
CIS who not progressed and 21.1 in CIS who progressed to MS
(Figure 2).
As expected, both the 2D- and the 3D-yrRTA were higher
in patients with CIS who progressed to MS than in controls or
patients with CIS who not progressed. Obviously, with this small
sample we cannot know if these differences are signiﬁcative or not.
Results of 2D- and 3D-yrRTAwere similar in controls andCISwho
not progressed. Results of 2D-yrRTA seem to be similar to those
of 3D-yrRTA in all groups.
ADVANTAGES AND LIMITATIONS OF THE yrRTA
From the clinician’s point of view, the yrRTA has the following
advantages over other methods:
FIGURE 2 | Mean 2D- and 3D-yrRTA in patients with CIS who
converted to MS over 24 months (CIS +), CIS who not converted (CIS)
and healthy controls. Values are merely illustrative -not informative-.
(1) Measurement and scoring of yrRTA is objective, providing a
distinct advantage over visual techniques.
(2) Volumetric measurements require the use of special soft-
ware, and much greater technical stringency in the acquisition
of the MRI scans and are far more prone to a variety of
measurement errors. Delineating the areas needed for cal-
culating the 2D-yrRTA is fast and easy; little training is
needed. This metric is very straightforward, therefore it
can be implemented for daily clinical practice using basic
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neuroimaging facilities currently available in most hospitals
with busy clinical settings.
(3) An additional advantage of using the yrRTA over absolute vol-
umetric measures is that regional brain volumes are variable
across individuals and need to be normalized by conversion to
a ratio of the absolute volumes to intracranial volume,whereas
the yrRTA has built-in normalization and thus avoids multi-
plicative errors inherent in using ratios of two quantitative
variables.
(4) The same way, as aging affects lateral ventricles -independent
of any pathology-, aging should be included as covariate in
methods providing absolute volumes or scores. The yrRTA
is an “intra-patient” ratio so it will not need cut-off scores
adjusted by age because each subject serves as their own
control.
On the other hand, the main limitation of the 2D-yrRTA is that
scoring is based on measurements performed on a single slice,
thereby providing a limited perspective of overall brain pathol-
ogy. However, the correlation of the 2D- with the 3D-yrRTA will
determine the validity of the 2D approach in this regard. It is
also expected that other conditions affecting the ventricular mor-
phology, such as hydrocephalus, can alter the interpretation of the
yrRTA.
This paper is a methodological description only. Cut-off values
have to be calculated for both the 2D- and the 3D-yrRTA and cor-
relation between the 2D and 3D method has to be proven. Then,
their use as a parameter for diagnosing MS in research and clinical
practice has to be validated. Particularly, prospective studies are
needed to assess the usefulness of the yrRTA as a parameter for
predicting progression in the different forms of MS and its cor-
relation with cognition and disability. It will be also interesting
to explore the potential role of the yrRTA as a potential param-
eter helpful in the selection of treatments and in monitoring the
efﬁcacy.
CONCLUSION
We report a new method for estimating deep GM atrophy in MS
that is objective, comprehensive and easy to apply using clini-
cally available neuroimaging. It may have some advantages over
traditional volumetric methods that still need to be evaluated.
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